📂 MONDAY – R&D Commercialization Screener: “When the Science Starts Paying Rent”

Research spending is easy.

Commercializing it is hard.

Companies can pour billions into AI, software, pharmaceuticals, robotics, aerospace, semiconductors, autonomous systems, and new products for years before shareholders discover whether the investment actually created economic value.

The inflection happens when yesterday’s R&D expense begins producing today’s revenue, margins, market share, and free cash flow.

Today’s Intel Drop searches for companies entering that transition.

Use this to find businesses where the investment phase may be turning into the monetization phase before Wall Street fully updates the model.

💡PROMPT TEXT:

(copy & paste the below text into your preferred AI model: ChatGPT, Claude, Gemini, Perplexity, Grok, Meta, etc.)

You are a senior buy-side equity analyst running an “R&D Commercialization” stock screen as of October 19, 2026.

GOAL:

Identify 12–20 U.S.-listed companies where elevated research, product-development, engineering, or technology spending during the previous 2–5 years appears to be producing measurable commercial returns now.

Do NOT simply find companies with high R&D spending.

Find businesses where historical investment is beginning to translate into:

- New revenue
- Higher market share
- Better pricing
- Higher gross profit
- Improving operating leverage
- New recurring revenue
- Stronger free cash flow

Use the latest available:

- 10-K and 10-Q filings
- R&D expense
- Capitalized development where applicable
- Earnings transcripts
- Product launches
- Segment revenue
- Gross margins
- Customer adoption
- Bookings
- Orders
- Market-share data
- Analyst estimates

STEP 1 — MEASURE THE HISTORICAL INVESTMENT

For each company review 3–5 years of:

- R&D expense
- R&D as % of revenue
- Engineering headcount where disclosed
- Technology capex
- Product-development spending
- Acquisition spending tied to innovation

Calculate or estimate cumulative investment where credible.

Classify historical investment:

- Moderate
- High
- Very High

STEP 2 — IDENTIFY WHAT THE MONEY BUILT

Map major investments into:

- New products
- New platforms
- AI capabilities
- New drugs / therapies
- Autonomous systems
- Semiconductor architectures
- Software products
- Manufacturing processes
- New markets
- New customer segments

Avoid crediting generic R&D with no identifiable commercial outcome.

STEP 3 — FIND COMMERCIALIZATION EVIDENCE

Look for:

- Revenue from new products
- Customer adoption
- Paid conversions
- Bookings
- Order growth
- Contract wins
- Market-share gains
- Pricing premiums
- Cross-selling
- Higher utilization

Classify commercialization:

- Proven
- Emerging
- Early
- Unproven

STEP 4 — TEST ECONOMIC QUALITY

Ask whether commercialization improves:

- Gross margin
- Contribution margin
- Operating margin
- Return on invested capital
- Free cash flow

A new product that grows revenue while destroying economics should receive a lower score.

STEP 5 — CALCULATE R&D YIELD

Where credible data exist, estimate directionally:

Incremental Revenue
divided by
Prior R&D Investment

and

Incremental Gross Profit
divided by
Prior R&D Investment.

Do not create false precision.

Use relative classifications:

- High R&D Yield
- Moderate
- Low
- Too Early to Judge

STEP 6 — IDENTIFY THE LAG

Estimate time between:

INVESTMENT

and

COMMERCIAL PAYOFF.

Classify:

- <2 years
- 2–3 years
- 3–5 years
- >5 years

STEP 7 — TEST WHETHER SPENDING CAN MODERATE

Determine whether future growth still requires:

- Rapidly rising R&D
- Stable R&D
- Lower R&D intensity

A powerful setup occurs when commercialization accelerates while R&D growth moderates.

STEP 8 — CHECK CONSENSUS

Compare:

- Revenue estimates
- EPS estimates
- Margin estimates
- Recent revisions
- Current valuation
- Historical valuation

Determine whether commercialization appears:

- Underappreciated
- Partially Recognized
- Fully Priced

STEP 9 — SCORE EACH COMPANY

Assign:

- Historical Investment Quality: 1–5
- Commercialization Evidence: 1–5
- Revenue Conversion: 1–5
- Margin Conversion: 1–5
- Market-Share Impact: 1–5
- R&D Yield: 1–5
- Consensus Blind Spot: 1–5
- Valuation Support: 1–5

Calculate:

R&D COMMERCIALIZATION SCORE: 1–10

BUILD THE COMMERCIALIZATION TABLE:

- Ticker
- Company
- Sector
- Major Historical Investment
- Product / Platform Created
- Commercialization Stage
- Revenue Evidence
- Margin Evidence
- Estimated R&D Yield
- Consensus Awareness
- Next Catalyst
- Opportunity Score
- Primary Invalidation Risk

THEN IDENTIFY:

1. Five strongest commercialization inflections
2. Three companies where prior R&D is producing operating leverage now
3. Three high-R&D companies with little evidence of commercial payoff
4. Three businesses where a new product could materially change the revenue mix
5. Two overlooked sectors where R&D productivity is improving
6. Two companies where investors may be demanding proof too early

Clearly distinguish:

- Reported facts
- Calculations
- Estimates
- Interpretation

Never invent product revenue, R&D figures, adoption metrics, or market share.

Output in a clean table + 3–5 sentence explanation why this matters right now.

END PROMPT

→ Submit to AI model to receive actionable output.

Blue Horseshoe loves AI-driven alpha. Use responsibly.

Sponsored by: StockPilot.io 🚀